User login
Top AGA Community patient cases
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.
In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
Which of the following patients needs a liver biopsy and why? (https://community.gastro.org/posts/23108)
Next steps for a Crohn’s patient (https://community.gastro.org/posts/23000)
Fecal calprotectin versus histology (https://community.gastro.org/posts/22969)
Collecting and sending specimen for disaccharidase assay (https://community.gastro.org/posts/23092)
Roundtables (https://community.gastro.org/discussions)
Q&A with CRC task force: Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps
View all upcoming Roundtables in the community at https://community.gastro.org/discussions.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.
In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
Which of the following patients needs a liver biopsy and why? (https://community.gastro.org/posts/23108)
Next steps for a Crohn’s patient (https://community.gastro.org/posts/23000)
Fecal calprotectin versus histology (https://community.gastro.org/posts/22969)
Collecting and sending specimen for disaccharidase assay (https://community.gastro.org/posts/23092)
Roundtables (https://community.gastro.org/discussions)
Q&A with CRC task force: Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps
View all upcoming Roundtables in the community at https://community.gastro.org/discussions.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.
In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
Which of the following patients needs a liver biopsy and why? (https://community.gastro.org/posts/23108)
Next steps for a Crohn’s patient (https://community.gastro.org/posts/23000)
Fecal calprotectin versus histology (https://community.gastro.org/posts/22969)
Collecting and sending specimen for disaccharidase assay (https://community.gastro.org/posts/23092)
Roundtables (https://community.gastro.org/discussions)
Q&A with CRC task force: Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps
View all upcoming Roundtables in the community at https://community.gastro.org/discussions.
This month in the journal CHEST®
Editor’s picks
Power Outage: An Ignored Risk Factor for Chronic Obstructive Pulmonary Disease ExacerbationsBy Dr. Wangjian Zhang, et al.
PROPHETIC: Prospective Identification of Pneumonia in Hospitalized Patients in the ICU By Dr. Stephen P. Bergin, et al.
Chronic Beryllium Disease: Update on a Moving Target By Dr. Maeve MacMurdo, et al.
Development of Learning Curves for Bronchoscopy: Results of a Multicenter Study of Pulmonary Trainees By Dr. Nha Voduc, et al.
Bias and Racism Teaching Rounds at an Academic Medical Center By Dr. Quinn Capers, IV, et al.
Editor’s picks
Editor’s picks
Power Outage: An Ignored Risk Factor for Chronic Obstructive Pulmonary Disease ExacerbationsBy Dr. Wangjian Zhang, et al.
PROPHETIC: Prospective Identification of Pneumonia in Hospitalized Patients in the ICU By Dr. Stephen P. Bergin, et al.
Chronic Beryllium Disease: Update on a Moving Target By Dr. Maeve MacMurdo, et al.
Development of Learning Curves for Bronchoscopy: Results of a Multicenter Study of Pulmonary Trainees By Dr. Nha Voduc, et al.
Bias and Racism Teaching Rounds at an Academic Medical Center By Dr. Quinn Capers, IV, et al.
Power Outage: An Ignored Risk Factor for Chronic Obstructive Pulmonary Disease ExacerbationsBy Dr. Wangjian Zhang, et al.
PROPHETIC: Prospective Identification of Pneumonia in Hospitalized Patients in the ICU By Dr. Stephen P. Bergin, et al.
Chronic Beryllium Disease: Update on a Moving Target By Dr. Maeve MacMurdo, et al.
Development of Learning Curves for Bronchoscopy: Results of a Multicenter Study of Pulmonary Trainees By Dr. Nha Voduc, et al.
Bias and Racism Teaching Rounds at an Academic Medical Center By Dr. Quinn Capers, IV, et al.
AGA Giving Day: Our fight to eradicate disparities in digestive diseases
On Dec. 3, AGA brought together the GI community in an effort to fund health disparity research with the goal of improving care for the patients who rely on us.
The patients we serve face racial health disparities daily. It’s our responsibility to take action. With money raised through this campaign, the AGA Research Foundation will fund research projects that help understand health disparities and create strategies for overcoming them.
AGA Giving Day was the opportunity to do something about this important societal issue as it directly relates to our field. We all have a role to play in creating a just world free of health disparities in digestive diseases and free of inequities in access and effective health care delivery.
The AGA Research Foundation’s AGA Giving Day effort will help support state-of-the-art research that aligns with the realities of the current multicultural patient population and disease states to achieve health equity for all.
Learn more at gastro.org/agagivingday.
On Dec. 3, AGA brought together the GI community in an effort to fund health disparity research with the goal of improving care for the patients who rely on us.
The patients we serve face racial health disparities daily. It’s our responsibility to take action. With money raised through this campaign, the AGA Research Foundation will fund research projects that help understand health disparities and create strategies for overcoming them.
AGA Giving Day was the opportunity to do something about this important societal issue as it directly relates to our field. We all have a role to play in creating a just world free of health disparities in digestive diseases and free of inequities in access and effective health care delivery.
The AGA Research Foundation’s AGA Giving Day effort will help support state-of-the-art research that aligns with the realities of the current multicultural patient population and disease states to achieve health equity for all.
Learn more at gastro.org/agagivingday.
On Dec. 3, AGA brought together the GI community in an effort to fund health disparity research with the goal of improving care for the patients who rely on us.
The patients we serve face racial health disparities daily. It’s our responsibility to take action. With money raised through this campaign, the AGA Research Foundation will fund research projects that help understand health disparities and create strategies for overcoming them.
AGA Giving Day was the opportunity to do something about this important societal issue as it directly relates to our field. We all have a role to play in creating a just world free of health disparities in digestive diseases and free of inequities in access and effective health care delivery.
The AGA Research Foundation’s AGA Giving Day effort will help support state-of-the-art research that aligns with the realities of the current multicultural patient population and disease states to achieve health equity for all.
Learn more at gastro.org/agagivingday.
Top AGA Community patient cases
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.
In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
Practice update: Small intestinal bacteria overgrowth (SIBO) (https://community.gastro.org/posts/22838)
Case: Polypectomy with low neutrophils (https://community.gastro.org/posts/22844)
Case: Esophagus adenocarcinoma after sleeve gastrectomy (https://community.gastro.org/posts/22868)
Case: Restarting infliximab after shingles – when is it safe? (https://community.gastro.org/posts/22890)
Case: Flatulence in Colorado (https://community.gastro.org/posts/22901)
Case: Serrated epithelial change (SEC) in IBD (https://community.gastro.org/posts/22948)
Case: Multiloculated pancreatic cyst (https://community.gastro.org/posts/22935)
View all upcoming Roundtables in the community at https://community.gastro.org/discussions.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.
In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
Practice update: Small intestinal bacteria overgrowth (SIBO) (https://community.gastro.org/posts/22838)
Case: Polypectomy with low neutrophils (https://community.gastro.org/posts/22844)
Case: Esophagus adenocarcinoma after sleeve gastrectomy (https://community.gastro.org/posts/22868)
Case: Restarting infliximab after shingles – when is it safe? (https://community.gastro.org/posts/22890)
Case: Flatulence in Colorado (https://community.gastro.org/posts/22901)
Case: Serrated epithelial change (SEC) in IBD (https://community.gastro.org/posts/22948)
Case: Multiloculated pancreatic cyst (https://community.gastro.org/posts/22935)
View all upcoming Roundtables in the community at https://community.gastro.org/discussions.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.
In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
Practice update: Small intestinal bacteria overgrowth (SIBO) (https://community.gastro.org/posts/22838)
Case: Polypectomy with low neutrophils (https://community.gastro.org/posts/22844)
Case: Esophagus adenocarcinoma after sleeve gastrectomy (https://community.gastro.org/posts/22868)
Case: Restarting infliximab after shingles – when is it safe? (https://community.gastro.org/posts/22890)
Case: Flatulence in Colorado (https://community.gastro.org/posts/22901)
Case: Serrated epithelial change (SEC) in IBD (https://community.gastro.org/posts/22948)
Case: Multiloculated pancreatic cyst (https://community.gastro.org/posts/22935)
View all upcoming Roundtables in the community at https://community.gastro.org/discussions.
CGH releases its first GI cancer-themed issue
Articles include guidance on cancer progression in Barrett’s esophagus patients, CRC surveillance, and HCC incidence and risk.
Clinical Gastroenterology and Hepatology (CGH) is proud to release its first themed issue on GI cancers. This “issue within an issue” includes a collection of articles, selected by editor-in-chief Dr. Fasiha Kanwal, that will provide you with practical research to help guide cancer prevention, surveillance and treatment decisions for your patients.
View the themed issue on CGH’s website. and access other curated collections on cghjournal.org.
How can we combat health disparities in GI?
Hear from Craig Munroe, MD, on why we all need to donate to AGA Giving Day, now through Dec. 3, in order to fund GI health disparities research.
“Health disparities exist and negatively impact patients every day across our country. Working to solve these inequities for the good of our patients and workforce is fundamental to our calling as physicians,” says Craig A. Munroe, MD, associate chief for clinical innovation, University of California, San Francisco, AGA Diversity Committee member, AGA Equity Project advisory board member. “Although we have made tremendous strides over the decades, there is still much more that needs to be done. Disparate systems of care and legacies of inequality continue to cause great harm.”
That is why AGA is bringing together the GI community to fund health disparity research with the goal of improving care for all patients. With contributions raised through AGA Giving Day campaign, the AGA Research Foundation will fund research projects that help us understand health disparities and create strategies for overcoming them.
“I’m donating to AGA Giving Day because I believe the work being done will have an immediate positive impact, and will continue to benefit future generations of patients, physicians, scientists, health providers, and trainees.”
Please join Dr. Munroe and your AGA colleagues in making a tax-deductible donation to the AGA Research Foundation to support AGA Giving Day today through Dec. 3. Contributors will be recognized as supporters of our fight to achieve equity and eradicate disparities in digestive diseases. www.Gastro.org/GivingDay
Articles include guidance on cancer progression in Barrett’s esophagus patients, CRC surveillance, and HCC incidence and risk.
Clinical Gastroenterology and Hepatology (CGH) is proud to release its first themed issue on GI cancers. This “issue within an issue” includes a collection of articles, selected by editor-in-chief Dr. Fasiha Kanwal, that will provide you with practical research to help guide cancer prevention, surveillance and treatment decisions for your patients.
View the themed issue on CGH’s website. and access other curated collections on cghjournal.org.
How can we combat health disparities in GI?
Hear from Craig Munroe, MD, on why we all need to donate to AGA Giving Day, now through Dec. 3, in order to fund GI health disparities research.
“Health disparities exist and negatively impact patients every day across our country. Working to solve these inequities for the good of our patients and workforce is fundamental to our calling as physicians,” says Craig A. Munroe, MD, associate chief for clinical innovation, University of California, San Francisco, AGA Diversity Committee member, AGA Equity Project advisory board member. “Although we have made tremendous strides over the decades, there is still much more that needs to be done. Disparate systems of care and legacies of inequality continue to cause great harm.”
That is why AGA is bringing together the GI community to fund health disparity research with the goal of improving care for all patients. With contributions raised through AGA Giving Day campaign, the AGA Research Foundation will fund research projects that help us understand health disparities and create strategies for overcoming them.
“I’m donating to AGA Giving Day because I believe the work being done will have an immediate positive impact, and will continue to benefit future generations of patients, physicians, scientists, health providers, and trainees.”
Please join Dr. Munroe and your AGA colleagues in making a tax-deductible donation to the AGA Research Foundation to support AGA Giving Day today through Dec. 3. Contributors will be recognized as supporters of our fight to achieve equity and eradicate disparities in digestive diseases. www.Gastro.org/GivingDay
Articles include guidance on cancer progression in Barrett’s esophagus patients, CRC surveillance, and HCC incidence and risk.
Clinical Gastroenterology and Hepatology (CGH) is proud to release its first themed issue on GI cancers. This “issue within an issue” includes a collection of articles, selected by editor-in-chief Dr. Fasiha Kanwal, that will provide you with practical research to help guide cancer prevention, surveillance and treatment decisions for your patients.
View the themed issue on CGH’s website. and access other curated collections on cghjournal.org.
How can we combat health disparities in GI?
Hear from Craig Munroe, MD, on why we all need to donate to AGA Giving Day, now through Dec. 3, in order to fund GI health disparities research.
“Health disparities exist and negatively impact patients every day across our country. Working to solve these inequities for the good of our patients and workforce is fundamental to our calling as physicians,” says Craig A. Munroe, MD, associate chief for clinical innovation, University of California, San Francisco, AGA Diversity Committee member, AGA Equity Project advisory board member. “Although we have made tremendous strides over the decades, there is still much more that needs to be done. Disparate systems of care and legacies of inequality continue to cause great harm.”
That is why AGA is bringing together the GI community to fund health disparity research with the goal of improving care for all patients. With contributions raised through AGA Giving Day campaign, the AGA Research Foundation will fund research projects that help us understand health disparities and create strategies for overcoming them.
“I’m donating to AGA Giving Day because I believe the work being done will have an immediate positive impact, and will continue to benefit future generations of patients, physicians, scientists, health providers, and trainees.”
Please join Dr. Munroe and your AGA colleagues in making a tax-deductible donation to the AGA Research Foundation to support AGA Giving Day today through Dec. 3. Contributors will be recognized as supporters of our fight to achieve equity and eradicate disparities in digestive diseases. www.Gastro.org/GivingDay
Congrats to these five AGA members
We’re proud to share the news of two AGA members elected to the prestigious National Academy of Medicine and three honored with the 2020 Sherman Prize.
Congratulations to AGA members Judy H. Cho, MD, and B. Mark Evers, MD, who were recently elected to the National Academy of Medicine.
Judy H. Cho, MD, professor of medicine at Icahn School of Medicine at Mount Sinai, New York, for “establishing that uncommon, loss-of-function variants in the microbial-sensing domain of NOD2 confer risk for Crohn’s disease, and identifying a loss-of-function allele in the IL-23 receptor that protects against Crohn’s disease and ulcerative colitis, leading to new, approved therapies.”
B. Mark Evers, MD, physician in chief of oncology service at University of Kentucky Healthcare, for “his expertise on intestinal hormones and hormonal arcades in oncogenesis. His seminal insights defined the role of gut hormones on normal physiology and metabolism, pioneering innovative understanding of neuroendocrine cell biology and the role of neurohormonal pathways in the development and progression of neuroendocrine tumors.”
Being selected to the Academy is one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
In addition, the 2020 Sherman Prize was awarded to the following three AGA members:
David Rubin, MD, AGAF, chief, section of gastroenterology, hepatology and nutrition at University of Chicago Medicine, for his “renown in the IBD community as a brilliant clinician, creative researcher, tireless advocate, and trailblazing educator.”
Gary Wu, MD, professor of medicine at University of Pennsylvania, Perelman School of Medicine, for “pioneering the study of the gut microbiome in IBD, publishing seminal research on the relationship between diet and the microbiome — enabling multiple areas of research into dietary interventions for IBD.“
Jessica Allegretti, MD, MPH, director of clinical trials at Brigham and Women’s Hospital, as a “highly regarded expert in the field of fecal microbiota transplantation (FMT) and microbiome therapeutics, establishing the therapy as an effective treatment in IBD patients with recurrent C. difficile.”
Presented by the Bruce and Cynthia Sherman Charitable Foundation, the Sherman Prize is awarded to experts in the field of Crohn’s disease and ulcerative colitis who have exhibited their commitment to advancing inflammatory bowel disease care and have dedicated their careers to overcome these diseases.
We’re proud to share the news of two AGA members elected to the prestigious National Academy of Medicine and three honored with the 2020 Sherman Prize.
Congratulations to AGA members Judy H. Cho, MD, and B. Mark Evers, MD, who were recently elected to the National Academy of Medicine.
Judy H. Cho, MD, professor of medicine at Icahn School of Medicine at Mount Sinai, New York, for “establishing that uncommon, loss-of-function variants in the microbial-sensing domain of NOD2 confer risk for Crohn’s disease, and identifying a loss-of-function allele in the IL-23 receptor that protects against Crohn’s disease and ulcerative colitis, leading to new, approved therapies.”
B. Mark Evers, MD, physician in chief of oncology service at University of Kentucky Healthcare, for “his expertise on intestinal hormones and hormonal arcades in oncogenesis. His seminal insights defined the role of gut hormones on normal physiology and metabolism, pioneering innovative understanding of neuroendocrine cell biology and the role of neurohormonal pathways in the development and progression of neuroendocrine tumors.”
Being selected to the Academy is one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
In addition, the 2020 Sherman Prize was awarded to the following three AGA members:
David Rubin, MD, AGAF, chief, section of gastroenterology, hepatology and nutrition at University of Chicago Medicine, for his “renown in the IBD community as a brilliant clinician, creative researcher, tireless advocate, and trailblazing educator.”
Gary Wu, MD, professor of medicine at University of Pennsylvania, Perelman School of Medicine, for “pioneering the study of the gut microbiome in IBD, publishing seminal research on the relationship between diet and the microbiome — enabling multiple areas of research into dietary interventions for IBD.“
Jessica Allegretti, MD, MPH, director of clinical trials at Brigham and Women’s Hospital, as a “highly regarded expert in the field of fecal microbiota transplantation (FMT) and microbiome therapeutics, establishing the therapy as an effective treatment in IBD patients with recurrent C. difficile.”
Presented by the Bruce and Cynthia Sherman Charitable Foundation, the Sherman Prize is awarded to experts in the field of Crohn’s disease and ulcerative colitis who have exhibited their commitment to advancing inflammatory bowel disease care and have dedicated their careers to overcome these diseases.
We’re proud to share the news of two AGA members elected to the prestigious National Academy of Medicine and three honored with the 2020 Sherman Prize.
Congratulations to AGA members Judy H. Cho, MD, and B. Mark Evers, MD, who were recently elected to the National Academy of Medicine.
Judy H. Cho, MD, professor of medicine at Icahn School of Medicine at Mount Sinai, New York, for “establishing that uncommon, loss-of-function variants in the microbial-sensing domain of NOD2 confer risk for Crohn’s disease, and identifying a loss-of-function allele in the IL-23 receptor that protects against Crohn’s disease and ulcerative colitis, leading to new, approved therapies.”
B. Mark Evers, MD, physician in chief of oncology service at University of Kentucky Healthcare, for “his expertise on intestinal hormones and hormonal arcades in oncogenesis. His seminal insights defined the role of gut hormones on normal physiology and metabolism, pioneering innovative understanding of neuroendocrine cell biology and the role of neurohormonal pathways in the development and progression of neuroendocrine tumors.”
Being selected to the Academy is one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
In addition, the 2020 Sherman Prize was awarded to the following three AGA members:
David Rubin, MD, AGAF, chief, section of gastroenterology, hepatology and nutrition at University of Chicago Medicine, for his “renown in the IBD community as a brilliant clinician, creative researcher, tireless advocate, and trailblazing educator.”
Gary Wu, MD, professor of medicine at University of Pennsylvania, Perelman School of Medicine, for “pioneering the study of the gut microbiome in IBD, publishing seminal research on the relationship between diet and the microbiome — enabling multiple areas of research into dietary interventions for IBD.“
Jessica Allegretti, MD, MPH, director of clinical trials at Brigham and Women’s Hospital, as a “highly regarded expert in the field of fecal microbiota transplantation (FMT) and microbiome therapeutics, establishing the therapy as an effective treatment in IBD patients with recurrent C. difficile.”
Presented by the Bruce and Cynthia Sherman Charitable Foundation, the Sherman Prize is awarded to experts in the field of Crohn’s disease and ulcerative colitis who have exhibited their commitment to advancing inflammatory bowel disease care and have dedicated their careers to overcome these diseases.
Experts release new management strategies for malignant colorectal polyps
Early identification and removal of cancerous colorectal polyps is critical to preventing the progression of colorectal cancer and improving survival rates. The U.S. Multisociety Task Force (U.S. MSTF) on Colorectal Cancer has released new guidance for endoscopists on how to assess colorectal lesions for features associated with cancer, discuss how these factors guide management and outline when to advise surgery after malignant polyp removal.
Key recommendations from the U.S. Multisociety Task Force on Colorectal Cancer, which is comprised of leading experts representing AGA, ACG and ASGE, include:
1. Management of malignant polyps must begin with a thorough and knowledgeable endoscopic assessment designed to identify features of deep submucosal invasion.
2. In nonpedunculated lesions with features of deep submucosal invasion, endoscopic biopsy and tattooing should be followed by surgical resection.
3. Nonpedunculated lesions with high risk of superficial submucosal invasion should be considered for en bloc resection and proper specimen handling.
4. When pathology reports cancer in a lesion that was completely resected endoscopically, the decision to recommend surgery is based on polyp shape, whether there was en bloc resection and adequate histologic assessment, the presence or absence of unfavorable histologic features, the patient’s risk for surgical mortality and morbidity, and patient preferences.
For more information, review the full publication: Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. The U.S. MSTF recommendations are published jointly in Gastroenterology, The American Journal of Gastroenterology, and Gastrointestinal Endoscopy.
Early identification and removal of cancerous colorectal polyps is critical to preventing the progression of colorectal cancer and improving survival rates. The U.S. Multisociety Task Force (U.S. MSTF) on Colorectal Cancer has released new guidance for endoscopists on how to assess colorectal lesions for features associated with cancer, discuss how these factors guide management and outline when to advise surgery after malignant polyp removal.
Key recommendations from the U.S. Multisociety Task Force on Colorectal Cancer, which is comprised of leading experts representing AGA, ACG and ASGE, include:
1. Management of malignant polyps must begin with a thorough and knowledgeable endoscopic assessment designed to identify features of deep submucosal invasion.
2. In nonpedunculated lesions with features of deep submucosal invasion, endoscopic biopsy and tattooing should be followed by surgical resection.
3. Nonpedunculated lesions with high risk of superficial submucosal invasion should be considered for en bloc resection and proper specimen handling.
4. When pathology reports cancer in a lesion that was completely resected endoscopically, the decision to recommend surgery is based on polyp shape, whether there was en bloc resection and adequate histologic assessment, the presence or absence of unfavorable histologic features, the patient’s risk for surgical mortality and morbidity, and patient preferences.
For more information, review the full publication: Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. The U.S. MSTF recommendations are published jointly in Gastroenterology, The American Journal of Gastroenterology, and Gastrointestinal Endoscopy.
Early identification and removal of cancerous colorectal polyps is critical to preventing the progression of colorectal cancer and improving survival rates. The U.S. Multisociety Task Force (U.S. MSTF) on Colorectal Cancer has released new guidance for endoscopists on how to assess colorectal lesions for features associated with cancer, discuss how these factors guide management and outline when to advise surgery after malignant polyp removal.
Key recommendations from the U.S. Multisociety Task Force on Colorectal Cancer, which is comprised of leading experts representing AGA, ACG and ASGE, include:
1. Management of malignant polyps must begin with a thorough and knowledgeable endoscopic assessment designed to identify features of deep submucosal invasion.
2. In nonpedunculated lesions with features of deep submucosal invasion, endoscopic biopsy and tattooing should be followed by surgical resection.
3. Nonpedunculated lesions with high risk of superficial submucosal invasion should be considered for en bloc resection and proper specimen handling.
4. When pathology reports cancer in a lesion that was completely resected endoscopically, the decision to recommend surgery is based on polyp shape, whether there was en bloc resection and adequate histologic assessment, the presence or absence of unfavorable histologic features, the patient’s risk for surgical mortality and morbidity, and patient preferences.
For more information, review the full publication: Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. The U.S. MSTF recommendations are published jointly in Gastroenterology, The American Journal of Gastroenterology, and Gastrointestinal Endoscopy.
Launching a virtual Listening Tour
How do we discuss race and lung health issues that impact our most deserving, underserved communities? Continuously and uncomfortably. As the Executive Director of the CHEST Foundation and as a young Black man, I am hopeful that we, as CHEST, can lead these uncomfortable conversations to better our communities. Our ability to listen and deliver support to our most-deserving communities is critical in how we fulfill our mission. CHEST continues to be a leader in lung health because we choose to give a voice and a platform in support of better lung health – especially to those who are disproportionately affected by lung disease, specifically addressing the quality of care they receive and bringing to light the fact that too often these patients are forgotten by the rest of society.
As cases of COVID-19 and civil unrest continue to swell across our nation, we, the CHEST Foundation, have launched a virtual Listening Tour. We are taking this pragmatic, and more importantly, passionate approach to addressing health disparities by identifying and addressing barriers and issues affecting our most deserving and disproportionately underserved communities. By bringing together these communities’ patients and caregivers, local leaders, involved businesses, and our CHEST members in a virtual community gathering, we intend to clearly define the needs of each community, elevate those needs to a national level, and work to collaborate with and support these local communities and leaders to address their most-pressing issues.
Stories are what connect us and move us forward. We are confident that this virtual Listening Tour will be an opportunity for constituents to tell their own stories and learn from each other, while allowing the CHEST organization, through the CHEST Foundation, to act as the arbiter for pulmonary health and provide a path forward to create equity for those suffering from chronic lung disease.
We need your support to challenge these longstanding disparities in chest medicine. Help us advance these critical conversations and move the needle toward equality by contributing today at chestfoundation.org/donate.
How do we discuss race and lung health issues that impact our most deserving, underserved communities? Continuously and uncomfortably. As the Executive Director of the CHEST Foundation and as a young Black man, I am hopeful that we, as CHEST, can lead these uncomfortable conversations to better our communities. Our ability to listen and deliver support to our most-deserving communities is critical in how we fulfill our mission. CHEST continues to be a leader in lung health because we choose to give a voice and a platform in support of better lung health – especially to those who are disproportionately affected by lung disease, specifically addressing the quality of care they receive and bringing to light the fact that too often these patients are forgotten by the rest of society.
As cases of COVID-19 and civil unrest continue to swell across our nation, we, the CHEST Foundation, have launched a virtual Listening Tour. We are taking this pragmatic, and more importantly, passionate approach to addressing health disparities by identifying and addressing barriers and issues affecting our most deserving and disproportionately underserved communities. By bringing together these communities’ patients and caregivers, local leaders, involved businesses, and our CHEST members in a virtual community gathering, we intend to clearly define the needs of each community, elevate those needs to a national level, and work to collaborate with and support these local communities and leaders to address their most-pressing issues.
Stories are what connect us and move us forward. We are confident that this virtual Listening Tour will be an opportunity for constituents to tell their own stories and learn from each other, while allowing the CHEST organization, through the CHEST Foundation, to act as the arbiter for pulmonary health and provide a path forward to create equity for those suffering from chronic lung disease.
We need your support to challenge these longstanding disparities in chest medicine. Help us advance these critical conversations and move the needle toward equality by contributing today at chestfoundation.org/donate.
How do we discuss race and lung health issues that impact our most deserving, underserved communities? Continuously and uncomfortably. As the Executive Director of the CHEST Foundation and as a young Black man, I am hopeful that we, as CHEST, can lead these uncomfortable conversations to better our communities. Our ability to listen and deliver support to our most-deserving communities is critical in how we fulfill our mission. CHEST continues to be a leader in lung health because we choose to give a voice and a platform in support of better lung health – especially to those who are disproportionately affected by lung disease, specifically addressing the quality of care they receive and bringing to light the fact that too often these patients are forgotten by the rest of society.
As cases of COVID-19 and civil unrest continue to swell across our nation, we, the CHEST Foundation, have launched a virtual Listening Tour. We are taking this pragmatic, and more importantly, passionate approach to addressing health disparities by identifying and addressing barriers and issues affecting our most deserving and disproportionately underserved communities. By bringing together these communities’ patients and caregivers, local leaders, involved businesses, and our CHEST members in a virtual community gathering, we intend to clearly define the needs of each community, elevate those needs to a national level, and work to collaborate with and support these local communities and leaders to address their most-pressing issues.
Stories are what connect us and move us forward. We are confident that this virtual Listening Tour will be an opportunity for constituents to tell their own stories and learn from each other, while allowing the CHEST organization, through the CHEST Foundation, to act as the arbiter for pulmonary health and provide a path forward to create equity for those suffering from chronic lung disease.
We need your support to challenge these longstanding disparities in chest medicine. Help us advance these critical conversations and move the needle toward equality by contributing today at chestfoundation.org/donate.
This month in the journal CHEST®
Editor’s picks
International perspective on the new 2019 IDSA/ATS CAP guideline: A critical appraisal by a global expert panel. By Dr. Mathias Pletz, et al.
Development of an accurate bedside swallowing evaluation decision tree algorithm for detecting aspiration in acute respiratory failure survivors. By Dr. Marc Moss, et al.
How I Do It: Managing fatigue in patients with interstitial lung disease. By Dr. Marlies Wijsenbeek, et al.
Life-threatening and non-life-threatening complications associated with coughing: A scoping review. By Dr. Richard S. Irwin, MD, Master FCCP, et al.
Obstructive Sleep Apnea in Professional Transport Operations: Safety, Regulatory, and Economic Impact. By Dr. Indira Gurubhagavatula, et al.
Editor’s picks
Editor’s picks
International perspective on the new 2019 IDSA/ATS CAP guideline: A critical appraisal by a global expert panel. By Dr. Mathias Pletz, et al.
Development of an accurate bedside swallowing evaluation decision tree algorithm for detecting aspiration in acute respiratory failure survivors. By Dr. Marc Moss, et al.
How I Do It: Managing fatigue in patients with interstitial lung disease. By Dr. Marlies Wijsenbeek, et al.
Life-threatening and non-life-threatening complications associated with coughing: A scoping review. By Dr. Richard S. Irwin, MD, Master FCCP, et al.
Obstructive Sleep Apnea in Professional Transport Operations: Safety, Regulatory, and Economic Impact. By Dr. Indira Gurubhagavatula, et al.
International perspective on the new 2019 IDSA/ATS CAP guideline: A critical appraisal by a global expert panel. By Dr. Mathias Pletz, et al.
Development of an accurate bedside swallowing evaluation decision tree algorithm for detecting aspiration in acute respiratory failure survivors. By Dr. Marc Moss, et al.
How I Do It: Managing fatigue in patients with interstitial lung disease. By Dr. Marlies Wijsenbeek, et al.
Life-threatening and non-life-threatening complications associated with coughing: A scoping review. By Dr. Richard S. Irwin, MD, Master FCCP, et al.
Obstructive Sleep Apnea in Professional Transport Operations: Safety, Regulatory, and Economic Impact. By Dr. Indira Gurubhagavatula, et al.
CHEST and ATS respond to proposed fee schedule
CHEST and the American Thoracic Society (ATS) submitted joint comments regarding the proposed Medicare Physician Fee Schedule for 2021 to CMS Administrator Seema Verma on topics of direct interest to members. The letter focuses on:
Medicare payment for critical care services: Further to the joint letter from CHEST, ATS, and the Society of Critical Care Medicine to Department of Health and Human Services Secretary Azar (see article in September 2020 Washington Watchline), the concerns related to the proposed 8% reduction in reimbursement for critical care services are explained, particularly relating to the role of critical care providers during the pandemic. They call for waiving budget neutrality or utilizing the public health emergency declaration to ensure appropriate patient care.
E/M payment changes: ATS and CHEST voice support for the proposed changes to evaluation and management (E/M) office visits and the increased reimbursement for the cognitive component of E/M medicine. They urge CMS to use its authority to waive the budget neutrality requirements while implementing the E/M changes.
Adoption of RUC-recommended values for pulmonary services: They urge CMS to finalize values for specific pulmonary services while acknowledging thanks for the adoption of the Relative Value Scale Update Committee (RUC)-recommended physician work values for a range of Current Procedural Terminology codes.
Telehealth services: While commending CMS for actions related to telehealth to provide care during the pandemic, they suggest it is now appropriate to sunset the telehealth listing for critical care services as providers have acquired additional experience in treating COVID-19.
GPC1X descriptors and utilization projections: They urge CMS to clarify the descriptors and seek additional comments on primary and ongoing health-care services.
Watch for reports of ongoing efforts from CHEST as the fee schedule process continues. Details of other activities in support of CHEST members appear in the November issue of Washington Watchline.
Reprinted from the November 2020 issue of Washington Watchline.
CHEST and the American Thoracic Society (ATS) submitted joint comments regarding the proposed Medicare Physician Fee Schedule for 2021 to CMS Administrator Seema Verma on topics of direct interest to members. The letter focuses on:
Medicare payment for critical care services: Further to the joint letter from CHEST, ATS, and the Society of Critical Care Medicine to Department of Health and Human Services Secretary Azar (see article in September 2020 Washington Watchline), the concerns related to the proposed 8% reduction in reimbursement for critical care services are explained, particularly relating to the role of critical care providers during the pandemic. They call for waiving budget neutrality or utilizing the public health emergency declaration to ensure appropriate patient care.
E/M payment changes: ATS and CHEST voice support for the proposed changes to evaluation and management (E/M) office visits and the increased reimbursement for the cognitive component of E/M medicine. They urge CMS to use its authority to waive the budget neutrality requirements while implementing the E/M changes.
Adoption of RUC-recommended values for pulmonary services: They urge CMS to finalize values for specific pulmonary services while acknowledging thanks for the adoption of the Relative Value Scale Update Committee (RUC)-recommended physician work values for a range of Current Procedural Terminology codes.
Telehealth services: While commending CMS for actions related to telehealth to provide care during the pandemic, they suggest it is now appropriate to sunset the telehealth listing for critical care services as providers have acquired additional experience in treating COVID-19.
GPC1X descriptors and utilization projections: They urge CMS to clarify the descriptors and seek additional comments on primary and ongoing health-care services.
Watch for reports of ongoing efforts from CHEST as the fee schedule process continues. Details of other activities in support of CHEST members appear in the November issue of Washington Watchline.
Reprinted from the November 2020 issue of Washington Watchline.
CHEST and the American Thoracic Society (ATS) submitted joint comments regarding the proposed Medicare Physician Fee Schedule for 2021 to CMS Administrator Seema Verma on topics of direct interest to members. The letter focuses on:
Medicare payment for critical care services: Further to the joint letter from CHEST, ATS, and the Society of Critical Care Medicine to Department of Health and Human Services Secretary Azar (see article in September 2020 Washington Watchline), the concerns related to the proposed 8% reduction in reimbursement for critical care services are explained, particularly relating to the role of critical care providers during the pandemic. They call for waiving budget neutrality or utilizing the public health emergency declaration to ensure appropriate patient care.
E/M payment changes: ATS and CHEST voice support for the proposed changes to evaluation and management (E/M) office visits and the increased reimbursement for the cognitive component of E/M medicine. They urge CMS to use its authority to waive the budget neutrality requirements while implementing the E/M changes.
Adoption of RUC-recommended values for pulmonary services: They urge CMS to finalize values for specific pulmonary services while acknowledging thanks for the adoption of the Relative Value Scale Update Committee (RUC)-recommended physician work values for a range of Current Procedural Terminology codes.
Telehealth services: While commending CMS for actions related to telehealth to provide care during the pandemic, they suggest it is now appropriate to sunset the telehealth listing for critical care services as providers have acquired additional experience in treating COVID-19.
GPC1X descriptors and utilization projections: They urge CMS to clarify the descriptors and seek additional comments on primary and ongoing health-care services.
Watch for reports of ongoing efforts from CHEST as the fee schedule process continues. Details of other activities in support of CHEST members appear in the November issue of Washington Watchline.
Reprinted from the November 2020 issue of Washington Watchline.